Endocrinology focuses on hormonal system and metabolic health. Learn about the diagnosis and treatment of diabetes, thyroid disorders, and adrenal conditions.
Send us all your questions or requests, and our expert team will assist you.
Effective Treatment and Management of gigantism requires a multidisciplinary approach that addresses the underlying hormonal excess, skeletal overgrowth, and associated health risks. This page is designed for patients, families, and healthcare professionals seeking a clear overview of the therapeutic pathways available at Liv Hospital for this rare endocrine disorder. Worldwide, fewer than 1 in 1 million individuals are diagnosed with gigantism, yet early intervention can dramatically improve long‑term outcomes and quality of life.
In the following sections we discuss the diagnostic process, therapeutic goals, surgical and medical options, radiotherapy advances, and the comprehensive follow‑up care that together constitute a robust treatment and management plan. Whether you are considering care in Istanbul or simply researching the condition, the information below outlines the evidence‑based strategies employed by our expert endocrinology and neurosurgery teams.
Gigantism results from excessive secretion of growth hormone (GH) before the epiphyseal growth plates close, most commonly due to a pituitary adenoma. Accurate diagnosis is the cornerstone of any treatment and management strategy.
Early detection enables timely treatment and management before irreversible skeletal changes occur, improving the likelihood of normal adult stature.
Successful therapy aims to normalize GH/IGF‑1 levels, reduce tumor size, and prevent complications such as cardiomyopathy, diabetes, and joint degeneration.
Each component of the treatment and management plan is tailored to the patient’s age, tumor characteristics, and overall health, ensuring a personalized pathway to recovery.
Surgery remains the first‑line intervention for most patients with a GH‑secreting pituitary adenoma, offering the most rapid reduction in hormone levels.
Performed through the nasal cavity, TSS provides direct access to the sellar region with minimal brain retraction.
Reserved for large or invasive tumors that cannot be safely removed via the transsphenoidal route.
At Liv Hospital, neurosurgeons employ image‑guided navigation and intra‑operative MRI to maximize tumor resection while preserving pituitary function, forming a critical pillar of comprehensive treatment and management.
When surgery is incomplete, contraindicated, or as an adjunct, pharmacological agents are essential to achieve hormonal control.
Regular monitoring of IGF‑1 and GH levels guides dose adjustments, forming an integral component of the overall treatment and management strategy.
For residual disease after surgery or when medical therapy fails, radiotherapy offers a non‑invasive option to achieve long‑term hormonal control.
Delivers low‑dose radiation over several weeks, gradually reducing GH secretion.
Techniques such as Gamma Knife or CyberKnife focus high‑dose radiation in a single session, shortening treatment time.
Liv Hospital’s radiation oncology team integrates the latest imaging and planning software to deliver precise, safe, and effective treatment and management for patients with persistent GH hypersecretion.
Long‑term success depends on continuous monitoring and supportive care that extends beyond direct tumor treatment.
By integrating these components, Liv Hospital ensures that every aspect of the patient’s health is addressed, completing a holistic treatment and management pathway for gigantism.
Liv Hospital is a JCI‑accredited, internationally recognized center offering a 360‑degree patient experience for international visitors. Our multidisciplinary teams combine expertise in endocrinology, neurosurgery, radiation oncology, and supportive care, delivering personalized protocols that align with the latest global guidelines. From visa assistance and airport transfers to interpreter services and comfortable accommodation, we streamline every step so patients can focus on recovery.
Ready to start your journey toward effective treatment and management of gigantism? Contact Liv Hospital’s dedicated International Patient Services team today to schedule a consultation and learn how our world‑class specialists can support you every step of the way.
Send us all your questions or requests, and our expert team will assist you.
The condition results from an over‑secreting growth hormone‑producing pituitary adenoma that stimulates excessive growth before epiphyseal closure. Diagnosis starts with a detailed history of rapid height gain and physical signs, followed by serum IGF‑1 measurement to gauge GH activity. An oral glucose tolerance test confirms lack of GH suppression, and magnetic resonance imaging of the sellar region locates the tumor. Early identification allows timely treatment, reducing irreversible skeletal changes and improving long‑term outcomes.
Therapeutic objectives focus on biochemical remission (GH < 1 ng/mL, IGF‑1 within reference range), tumor control to avoid mass‑effect symptoms, preservation of visual and neurological function, and optimization of final stature while maintaining proportional growth. Secondary benefits include improved metabolic profile, reduced cardiovascular risk, and enhanced psychosocial wellbeing. Treatment plans are individualized based on age, tumor size, and overall health.
Transsphenoidal surgery (TSS) accesses the pituitary through the nasal cavity, offering minimal invasiveness, shorter hospital stays (2–4 days), and remission rates of 60–80 % after the first operation. Open craniotomy is reserved for macroadenomas that cannot be safely removed via TSS, involving longer stays (7–10 days) and higher complication rates (15–25 %). At Liv Hospital, image‑guided navigation and intra‑operative MRI enhance resection while preserving pituitary function.
Somatostatin analogues such as octreotide and lanreotide suppress GH secretion, while GH‑receptor antagonists like pegvisomant block peripheral GH action. Dopamine agonists (e.g., cabergoline) provide modest GH reduction, especially in mixed adenomas. Combination therapy can improve remission when single agents are insufficient. Doses are titrated based on regular IGF‑1 and GH monitoring to achieve hormonal control.
Conventional fractionated radiotherapy delivers low‑dose radiation over weeks, achieving hormonal control in 3–5 years with remission rates of 55–70 % but carries a risk of hypopituitarism. Stereotactic radiosurgery (Gamma Knife or CyberKnife) provides a high‑dose single session, achieving control in 12–24 months with 60–80 % remission and low necrosis risk. Proton beam therapy offers precise dose distribution with limited tissue exposure, showing 65–85 % remission, though long‑term data are limited. Liv Hospital employs advanced imaging and planning for safe delivery.
The surveillance protocol includes quarterly IGF‑1 and GH assays during the first year, annual MRI to detect residual or recurrent tumor, and bone‑age assessment in children. Lifestyle support—nutrition counseling, physical therapy, and psychological services—addresses metabolic health and psychosocial wellbeing. Follow‑up visits are scheduled every 3–6 months with an endocrinologist, annually with a neurosurgeon, semi‑annually with a radiation oncologist (first two years), and bi‑annually with a dietitian, ensuring comprehensive, ongoing care.
BlogEndocrinologyApr 23, 2026Adrenal masses require careful evaluation. Understand the signs, symptoms, and importance of gh levels in d...
BlogEndocrinologyApr 23, 2026Discover the truth about epinephrine and how EpiPens work in anaphylaxis. Our expert guide explains the sci...
BlogEndocrinologyApr 14, 2026Understand the impact of elevated cortisol on your blood pressure and learn how to keep cortisol levels in ...
BlogEndocrinologyApr 14, 2026Discover the causes and effects of persistent hyponatremia, and learn how low sodium levels can impact your...
BlogEndocrinologyApr 13, 2026Discover the essential role of antidiuretic hormone (ADH) in regulating fluid balance. Our complete guide e...
BlogEndocrinologyApr 13, 2026Learn about SIADH, the condition where your body produces too much antidiuretic hormone. Discover causes, s...
